Neuroptix Corporation


Press Releases

November 4, 2009

Neuroptix Corp. Announces Addition of Werner Schaefer
to Board of Directors

Diagnostics industry veteran joins board of pioneer in non-invasive
early detection of Alzheimer’s Disease

Acton, Massachusetts – November 4, 2009 – Neuroptix Corporation, a Massachusetts-based pioneer in the early detection of Alzheimer’s disease, today announced that the successful diagnostics executive Dr. Werner Schaefer has joined the company’s Board of Directors.

Paul Hartung, President and CEO of Neuroptix Corp. said, “Dr. Schaefer brings a wealth of experience in development and commercialization of diagnostic technologies to the Board of Directors at Neuroptix.  We are proud to have someone of his caliber join us, as he will add great value and new perspective to our already strong board.”

Dr. Schaefer has nearly 30 years of international management experience in the diagnostics sector, including general management, marketing and R&D. He has held senior positions such as President of the Lab Systems Business Unit of Boehringer Mannheim, acquired by Roche Diagnostics GmbH, and served as member of the Management Board of Roche Diagnostics GmbH, President and Chief Operating Officer of Behring Diagnostics, USA and Director of Area Operations and Scientific Development at Abbott GmbH Diagnostics.  Until recently he was on the board of, and headed U.S. operations for, B.R.A.H.M.S., which announced its acquisition for $470M by Thermo Fisher Scientific.  Dr. Schaefer now acts as a consultant to the biotech and diagnostics industry and is a member of various boards.

About Neuroptix Corporation

Neuroptix is creating and developing an innovative, non-invasive eye test to assist in the early diagnosis of Alzheimer’s Disease. Neuroptix’s goal is to provide clinicians with a quick, reliable, inexpensive and widely available test, enabling early diagnosis and treatment. The company maintains an active interest in collaboration with major pharmaceutical companies to facilitate testing of new Alzheimer’s drugs, and with academic institutions to promote research in this area.

For more information, please visit our website at, email us at, or call us at (978) 263-0005.


#  #  #